Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 407

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 407
---
, Heritas Argentina entered into a new lease for laboratory and office space for a 3 -yearperiod with CIBIC. The expected lease commitments resulting from this contract are $158,994 for the entire contractual period. On October 1, 2024, we sent a letter to LOCUS BIO SA expressing our intention to terminate the co -workingspace lease agreement signed on February 1, 2024. Loan Amendments and Credit Line Extensions On October 23, 2024, Heritas Argentina amended its existing loan agreements with CIBIC and Bioceres S.A. to incorporate credit line extensions, increasing the amount available under the Bioceres S.A. credit line to $820,000 and the CIBIC credit line to the total of $1,106,685.91, ensuring access to sufficient funds to support the subsidiary’s operational and strategic initiatives prior to the Closing. 217 Business of APx and Certain Information About APx References in this section to “we”, “our”, “us”, the “Company”, or “APx” generally refer to APx Acquisition Corp. I. Overview APx is a blank check company incorporated as a Cayman Islands exempted company on May 13, 2021, whose business purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. APx is not limited to a particular industry or geographic region in its identification and acquisition of a target company. The Sponsor is a Tennessee limited liability company that holds Founder Shares and the Private Warrants. The Sponsor has no business operations or activities other than holding Founder Shares and the Private Warrants. However, the Sponsor has made, and may make in the future, loans to APx to provide APx with the funds necessary for the payment of working capital expenses. The registration statement for the IPO was declared effective on December 6, 2021. On December 9, 2021, APx consummated its IPO of 17,250,000 units (the “SPAC Units”), including the issuance of 2,250,000 SPAC Units as a result of the underwriters’ exercise of their over -allotmentoption in full. Each SPAC Unit consists of one SPAC Class A Ordinary Share, par value $0.0001 per share, and one -halfof one redeemable warrant of APx (each whole warrant, a “Public Warrant”), with each Public W